PMID- 30306202
OWN - NLM
STAT- MEDLINE
DCOM- 20190128
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 68
IP  - 1
DP  - 2019 Jan
TI  - Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell 
      vaccination-based immunotherapy in patients with advanced cancer.
PG  - 121-130
LID - 10.1007/s00262-018-2257-2 [doi]
AB  - Dendritic cell (DC)-based immunotherapies have been created for a broad expanse 
      of cancers, and DC vaccines prepared with Wilms' tumor protein 1 (WT1) peptides 
      have shown great therapeutic efficacy in these diseases. In this paper, we report 
      the results of a phase I/II study of a DC-based vaccination for advanced breast, 
      ovarian, and gastric cancers, and we offer evidence that patients can be 
      effectively vaccinated with autologous DCs pulsed with WT1 peptide. There were 
      ten patients who took part in this clinical study; they were treated biweekly 
      with a WT1 peptide-pulsed DC vaccination, with toxicity and clinical and 
      immunological responses as the principal endpoints. All of the adverse events to 
      DC vaccinations were tolerable under an adjuvant setting. The clinical response 
      was stable disease in seven patients. Karnofsky Performance Scale scores were 
      enhanced, and computed tomography scans revealed tumor shrinkage in three of 
      seven patients. Human leukocyte antigen (HLA)/WT1-tetramer and cytoplasmic IFN-gamma 
      assays were used to examine the induction of a WT-1-specific immune response. The 
      immunological responses to DC vaccination were significantly correlated with 
      fewer myeloid-derived suppressor cells (P = 0.045) in the pretreated peripheral 
      blood. These outcomes offered initial clinical evidence that the WT1 
      peptide-pulsed DC vaccination is a potential treatment for advanced cancer.
FAU - Zhang, Wen
AU  - Zhang W
AD  - Department of Oncology, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, No. 17 South Lane, Panjiayuan, Chaoyang District, Beijing, 
      100021, China.
FAU - Lu, Xu
AU  - Lu X
AD  - Department of Oncology, Beijing Biohealthcare Biotechnology Co.,Ltd, FL2, 
      Building 3, Park B, Shunyi District Airport High Tech Zoon, Beijing, 101300, 
      China.
FAU - Cui, Peilin
AU  - Cui P
AD  - Department of Gastroenterology, Beijing Tiantan Hospital, Capital Medical 
      University, Beijing, 100050, China.
FAU - Piao, Chunmei
AU  - Piao C
AD  - Department of Oncology, Beijing Institute of Heart Lung and Blood Vessel 
      Diseases, Beijing Anzhen Hospital Affiliated to the Capital Medical University, 
      Beijing, 100029, China.
FAU - Xiao, Man
AU  - Xiao M
AD  - Department of Biochemistry and Molecular Biology, Hainan Medical College, Haikou, 
      571199, China.
FAU - Liu, Xuesong
AU  - Liu X
AD  - Department of Oncology, Beijing Biohealthcare Biotechnology Co.,Ltd, FL2, 
      Building 3, Park B, Shunyi District Airport High Tech Zoon, Beijing, 101300, 
      China.
FAU - Wang, Yue
AU  - Wang Y
AD  - Department of Oncology, Beijing Biohealthcare Biotechnology Co.,Ltd, FL2, 
      Building 3, Park B, Shunyi District Airport High Tech Zoon, Beijing, 101300, 
      China.
FAU - Wu, Xuan
AU  - Wu X
AD  - Department of Oncology, Beijing Biohealthcare Biotechnology Co.,Ltd, FL2, 
      Building 3, Park B, Shunyi District Airport High Tech Zoon, Beijing, 101300, 
      China.
FAU - Liu, Jingwei
AU  - Liu J
AD  - Department of Oncology, Beijing Biohealthcare Biotechnology Co.,Ltd, FL2, 
      Building 3, Park B, Shunyi District Airport High Tech Zoon, Beijing, 101300, 
      China. ljwgirl361@163.com.
FAU - Yang, Lin
AU  - Yang L
AUID- ORCID: 0000-0002-5954-8500
AD  - Department of Oncology, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, No. 17 South Lane, Panjiayuan, Chaoyang District, Beijing, 
      100021, China. 403182179@qq.com.
LA  - eng
GR  - 81770468/the National Natural Science Foundation of China/
GR  - 7162030/Beijing Municipal Natural Science Foundation/
GR  - Z14010101101/Beijing Science and Technology Plan special issue/
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
DEP - 20181010
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Cancer Vaccines)
RN  - 0 (WT1 Proteins)
RN  - 0 (WT1 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Breast Neoplasms/immunology/therapy
MH  - Cancer Vaccines/*immunology
MH  - Dendritic Cells/*immunology
MH  - Female
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/immunology/*therapy
MH  - Ovarian Neoplasms
MH  - Stomach Neoplasms/immunology/therapy
MH  - Treatment Outcome
MH  - Vaccination/methods
MH  - WT1 Proteins/*immunology
PMC - PMC11028035
OTO - NOTNLM
OT  - Cytotoxic T lymphocytes
OT  - Dendritic cell
OT  - Immunotherapy
OT  - Tumor-associated antigens
OT  - WT1
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2018/10/12 06:00
MHDA- 2019/01/29 06:00
PMCR- 2018/10/10
CRDT- 2018/10/12 06:00
PHST- 2017/11/06 00:00 [received]
PHST- 2018/10/04 00:00 [accepted]
PHST- 2018/10/12 06:00 [pubmed]
PHST- 2019/01/29 06:00 [medline]
PHST- 2018/10/12 06:00 [entrez]
PHST- 2018/10/10 00:00 [pmc-release]
AID - 10.1007/s00262-018-2257-2 [pii]
AID - 2257 [pii]
AID - 10.1007/s00262-018-2257-2 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2019 Jan;68(1):121-130. doi: 
      10.1007/s00262-018-2257-2. Epub 2018 Oct 10.